MedTrace Logo

FQ Restriction for the Prevention of CDI

NCT03848689 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5871

Last updated 2025-01-31

No results posted yet for this study

Summary

This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several Wisconsin ICUs and compare whether the intervention has improved outcomes in reducing CDIs. An additional goal of the study is to evaluate environmental and work system factors using systems engineering models in order to determine the most successful way to implement these new strategies.

Conditions

  • Clostridium Difficile
  • Clostridium Difficile Infection
  • C Difficile Colitis

Interventions

OTHER

fluoroquinolone preprescription authorization

Requires authorization from Infection Control consult prior to prescribing fluoroquinolone

OTHER

Control

Does not require authorization from Infection Control prior to prescribing fluoroquinolone

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    collaborator FED

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Nasia Safdar, MD PhD · University of Wisconsin, Madison

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03848689 on ClinicalTrials.gov